Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

The Lancet. Oncology·2026
Same author

Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Nature·2026
Same author

ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming.

The Journal of clinical investigation·2026
Same author

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.

Cancer discovery·2026
Same author

TMPO promotes cellular dissemination and metastasis in circulating tumor cells.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Jun 3, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

癌症的战争正在不断发展.

Daniel A Haber1, Nathanael S Gray, Jose Baselga

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA. haber@helix.mgh.harvard.edu

Cell
|April 5, 2011
PubMed
概括
此摘要是机器生成的。

癌症遗传学和药物化学的最新进展正在彻底改变癌症治疗. 来自罕见癌症的新分子洞察力正在迅速塑造新兴的癌症疗法,可能标志着一个转折点.

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

相关实验视频

Last Updated: Jun 3, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

科学领域:

  • 在瘤学瘤学.
  • 癌症遗传学 癌症遗传学
  • 药用化学 医学化学

背景情况:

  • 基本的科学发现为当前的进步奠定了基础.
  • 最近癌症遗传学和药物化学的进展正在趋同.
  • 在罕见的癌症子组中进行偶然的观测已经带来了新的见解.

研究的目的:

  • 突出癌症治疗临床研究的范式转变.
  • 讨论分子洞察力对新兴癌症疗法的快速应用.
  • 探索癌症治疗策略的转折点的潜力.

主要方法:

  • 审查癌症遗传学的最新进展.
  • 对药物化学发展的分析.
  • 检查分子洞察力转化为临床实践的研究.

主要成果:

  • 癌症遗传学和药物化学的融合正在彻底改变治疗方法.
  • 新兴疗法正在通过新的分子洞察力来塑造.
  • 临床研究中的范式转变正在进行中.

结论:

  • 基础科学和临床研究的整合标志着一个显著的进步.
  • 新兴的癌症疗法有望改善患者的治疗结果.
  • 这种趋同可能是抗击癌症的关键时刻.